SereNeuro Therapeutics
CompanyUnited States
SereNeuro Therapeutics develops one asset, preclinical (SN101 in chronic joint pain). Mostly cell therapy; based in the United States.
- 1
- Asset
- Furthest stage
- Preclinical
- 0
- Trials
- 0
- Signals
Pipeline
1iPSC-derived non-opioid cell therapy for chronic joint pain
Preclinical, Cell therapy, chronic joint pain
Full company profiles: pipeline, trials, funding and people.